GILD

Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences, Inc. (NASDAQ: GILD) ended the regular session on Monday, December 22, 2025 essentially flat, and the stock showed only a modest change in post-market trading—yet the news flow behind the scenes was anything but quiet. After the closing

23 December 2025

Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Ahead of the U.S. market open on Monday, December 22, 2025 (the next trading session after Friday’s close), Gilead Sciences, Inc. (NASDAQ: GILD) is in focus for two reasons that matter to both short-term traders and long-term investors: a new

22 December 2025

Financial News · Gilead Sciences · Investing · Market Analysis · Stock Market

Gilead Sciences (GILD) Stock Today: Price, Fresh News and Analyst Outlook on December 8, 2025

As of Monday, December 8, 2025, Gilead Sciences, Inc. (NASDAQ: GILD) sits near the upper end of its 52‑week range, supported by strong HIV franchises, new long‑acting prevention drugs, high‑profile cancer data at ASH 2025 and a steady dividend. At

8 December 2025

Analyst Ratings · Biotech · Market Analysis · NASDAQ:GILD · Pharmaceutical Stocks · Stock News

Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (NASDAQ: GILD) heads into Monday’s session riding an event‑packed weekend: new cancer data at the ASH 2025 hematology meeting, fresh institutional‑ownership filings, and another round of valuation work from analysts and quant platforms. Here’s what investors should know

8 December 2025

Biotechnology · Financial News · Gilead Sciences · Investing · NASDAQ:GILD · Stock Market

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences stock (NASDAQ: GILD) is trading near the upper end of its 52‑week range as of early December 2025, supported by stronger guidance, big HIV and liver franchises, and a mixed but important year for its oncology pipeline. At

6 December 2025

Dividends · Financial News · Investment Analysis · NASDAQ:GILD · Pharmaceuticals · Stock Market